Synaptic Vesicle Cycle
Overview
The synaptic vesicle cycle is the fundamental process by which neurotransmitters are packaged, transported, released, and recycled at presynaptic terminals. This cycle is essential for neurotransmission and involves coordinated interactions between hundreds of proteins that ensure precise temporal control of neurotransmitter release.
The Complete Synaptic Vesicle Cycle
Mermaid diagram (expand to render)
Stage 1: Vesicle Biogenesis and Acidification
Synaptic vesicles are generated from the Golgi apparatus and pre-synaptic plasma membrane through a process involving:
- Clathrin-mediated budding from endosomes
- Phosphatidylinositol metabolism (PI(4,5)P₂, PI(3,4,5)P₃)
- Dynamin GTPase for membrane scission
V-ATPase and Acidification
The vacuolar-type H⁺-ATPase (V-ATPase) pumps protons into the vesicle lumen, creating:
- Electrochemical gradient (ΔpH ≈ 0.6)
- Membrane potential (Δψ ≈ 40 mV)
- Driving force for neurotransmitter uptake
Stage 2: Neurotransmitter Loading
Vesicular Transporters
Different neurotransmitters use specific vesicular transporters:
| Transporter | Gene | Neurotransmitter | Location |
|-------------|------|-----------------|----------|
| VGLUT1 | SLC17A6 | Glutamate | Excitatory neurons |
| VGLUT2 | SLC17A6 | Glutamate | Thalamus, brainstem |
| VGLUT3 | SLC17A7 | Glutamate | Monoamine neurons |
| VMAT2 | SLC18A2 | Dopamine, Serotonin, Norepinephrine | Aminergic neurons |
| VIAAT | SLC32A1 | GABA, Glycine | Inhibitory neurons |
| VAChT | SLC18A3 | Acetylcholine | Cholinergic neurons |
Loading Mechanism
- Secondary active transport: Transporters use the H⁺ gradient
- Exchange: 2 H⁺ exchanged per neurotransmitter molecule
- Stoichiometry: ~10,000 neurotransmitters per vesicle (glutamate)
Stage 3: Vesicle Transport and Docking
Active Zone Architecture
The active zone is a specialized presynaptic structure containing:
- RIM proteins (RIM1, RIM2): Recruiting Ca²⁺ channels
- Munc13: Priming vesicles
- Munc18: Syntaxin binding
- ELKS/CAST: Scaffold proteins
- Piccolo/Achino: Cytoskeletal anchoring
Vesicle Docking
Docking involves:
Rab effectors: Rab3-GTP interacts with RIM
t-SNARE recruitment: Syntaxin to plasma membrane
v-SNARE formation: Synaptobrevin on vesicle
Munc13-Munc18 complex: Promoting SNARE assemblyStage 4: Priming and SNARE Complex Assembly
SNARE Complex Structure
The SNARE complex consists of:
| SNARE Protein | Type | Gene | Structure |
|---------------|------|------|-----------|
| Synaptobrevin-2 (VAMP2) | v-SNARE | VAMP2 | R-SNARE (Arg) |
| Syntaxin-1 | t-SNARE | STX1 | Q-SNARE (Gln) |
| SNAP-25 | t-SNARE | SNAP25 | Q-SNARE (Gln) × 2 |
Assembly Process
Mermaid diagram (expand to render)
Energy Requirements
- Zippering energy: ~35 kT per SNARE complex
- Coordinating complex: Complexin, Munc13
- Inhibition: Botulinum neurotoxins cleave SNARE proteins
Stage 5: Ca²⁺-Triggered Fusion
Synaptotagmin Family
Synaptotagmin (SYT) is the primary Ca²⁺ sensor:
| Protein | Ca²⁺ Binding | Function |
|---------|--------------|----------|
| Synaptotagmin-1 | C2A, C2B domains | Fast synchronous release |
| Synaptotagmin-2 | C2A, C2B domains | Similar to SYT1 |
| Synaptotagmin-7 | C2A, C2B domains | Asynchronous release |
| Synaptotagmin-9 | C2A, C2B domains | Partial compensation |
Fusion Mechanism
Ca²⁺ entry: Through voltage-gated calcium channels (VGCC)
Synaptotagmin binding: Ca²⁺ binds C2 domains
Membrane penetration: Hydrophobic loops insert into membranes
SNARE acceleration: Synaptotagmin displaces complexin
Fusion pore opening: Hemifusion intermediate forms
Full fusion: Pore expands, vesicle collapsesStage 6: Neurotransmitter Release
Release Quantal Properties
- Quantum: Contents of single vesicle (~10,000 molecules)
- Quantal size: Response amplitude per vesicle
- Release probability (Pᵣ): Typically 0.1-0.9
- Miniature events (mEPSPs): Spontaneous release
Kinetics
- Synchronous release: <1 ms after Ca²⁺ entry
- Asynchronous release: 10-100 ms delay
- Facilitation: Pᵣ increases with repeated stimuli
- Depression: Pᵣ decreases with high frequency
Stage 7: Endocytosis
After fusion, vesicle membrane is retrieved through:
Coat assembly: Clathrin triskelions + adaptin (AP2)
Cargo selection: SNARE proteins as internalization signals
Membrane curvature: Amphiphysin, endophilins
Scission: Dynamin GTP hydrolysis
Uncoating: Hsc70, auxilinAlternative Pathways
- Kiss-and-run: Fusion pore opens briefly, closes
- Bulk endocytosis: Large membrane infoldings
- Activity-dependent bulk endocytosis: During intense stimulation
Stage 8: Vesicle Recycling
Recycling Pathways
Direct reuse: Vesicle refilled without full cycle
Endosomal sorting: Via early endosomes
Local recycling: At active zone periphery
Global pool: Full pool replenishmentRe-acidification
- V-ATPase pumps restore H⁺ gradient
- Transporter reloading
- Ready for next release cycle
Key Proteins and Genes
| Protein | Gene | Function | Page |
|---------|------|----------|------|
| Synaptophysin | SYP | Major SV protein | [/proteins/synaptophysin](/proteins/synaptophysin) |
| Synaptotagmin-1 | SYT1 | Ca²⁺ sensor | (create) |
| VAMP2 | VAMP2 | v-SNARE | (create) |
| SNAP-25 | SNAP25 | t-SNARE | [/genes/snap25](/genes/snap25), [/proteins/snap25-protein](/proteins/snap25-protein) |
| Syntaxin-1 | STX1 | t-SNARE | (create) |
| Munc13-1 | UNC13B | Vesicle priming | (create) |
| Munc18-1 | STXBP1 | Syntaxin binding | [/proteins/stxbp1](/proteins/stxbp1) |
| Rab3A | RAB3A | Vesicle transport | (create) |
| Dynamin-1 | DNM1 | Membrane scission | (create) |
| Clathrin heavy chain | CLTC | Coat protein | (create) |
Regulation
Short-Term Plasticity
- Facilitation: Increased Pᵣ from residual Ca²⁺
- Depression: Vesicle pool depletion
- Augmentation: Medium-term enhancement
- Potentiation: Long-term enhancement
Long-Term Regulation
- Synaptic activity modulates protein expression
- Neuromodulators alter release probability
- Homeostatic scaling adjusts for activity changes
Disease Implications
Neurodegenerative Diseases
Dysregulation of the synaptic vesicle cycle is implicated in:
- Alzheimer's Disease: Amyloid-β disrupts SNARE complex
- Parkinson's Disease: α-Synuclein binds to vesicles
- ALS: Synaptic vesicle depletion
Therapeutic Targets
- VMAT2: L-DOPA treatment in PD
- Botulinum toxins: Therapeutic paralysis
- Calcium modulators: Altering release properties
Alzheimer's Disease and Synaptic Vesicle Dysfunction
Amyloid-β Impact on Synaptic Transmission
Alzheimer's disease (AD) represents one of the most extensively studied neurodegenerative conditions with respect to synaptic vesicle cycle disruption. Amyloid-beta (Aβ) peptides, the hallmark aggregating species in AD, directly interact with multiple components of the synaptic machinery. Research has demonstrated that Aβ oligomers bind to presynaptic terminals and impair neurotransmitter release through several mechanisms[@jack2023]:
SNARE Complex Disruption: Aβ oligomers bind to syntaxin-1 and SNAP-25, disrupting the formation and stability of the SNARE complex. This impairment reduces the efficiency of vesicle fusion and diminishes synaptic transmission. The C-terminal region of Aβ shows particular affinity for the SNARE proteins, leading to misfolding and aggregation that sequesters these critical components[@chen2019].
Synaptotagmin-1 Impairment: Aβ interferes with synaptotagmin-1's calcium-binding capacity, reducing its efficacy as a calcium sensor. This directly impacts the rapid, synchronous neurotransmitter release that is essential for proper synaptic communication.
Vesicle Pool Depletion: Chronic Aβ exposure reduces the size of the readily releasable pool (RRP) of synaptic vesicles, limiting the capacity for sustained synaptic transmission during periods of high activity.
Tau Pathology and Synaptic Vesicles
Hyperphosphorylated tau protein, forming neurofibrillary tangles in AD, also contributes to synaptic vesicle cycle dysfunction. Tau localizes to presynaptic terminals where it can:
Disrupt vesicle trafficking: Tau interferes with the molecular motors that transport vesicles along microtubules
Alter neurotransmitter release: Tau reduces the density of synaptic vesicles at the active zone
Impair vesicle recycling: Endocytosis pathways are compromised by tau pathologyParkinson's Disease and Synaptic Vesicle Dysfunction
Alpha-Synuclein and Presynaptic Function
Parkinson's disease (PD) is intrinsically linked to synaptic vesicle dysfunction through the aggregation of alpha-synuclein (α-syn) at presynaptic terminals. α-Syn is a natively unstructured protein that under pathological conditions forms oligomers and fibrils that disrupt normal synaptic function[@calahorra2021]:
SNARE Complex Binding: α-Syn directly binds to synaptobrevin-2 (VAMP2) and other SNARE proteins. At physiological concentrations, this interaction may serve a regulatory role; however, under pathological conditions, α-syn aggregation sequesters SNARE components and impairs complex assembly[@burr2015].
Vesicle Membrane Interactions: α-Syn has high affinity for acidic phospholipids in synaptic vesicle membranes. Pathological mutations (A53T, A30P) accelerate membrane binding and promote oligomerization that disrupts vesicle integrity and function.
Dopaminergic Synaptic Specificity: In PD, substantia nigra dopaminergic neurons are particularly vulnerable due to their unique synaptic physiology:
- High basal firing rates require sustained vesicle cycling
- Reliance on precise timing of neurotransmitter release
- Limited compensatory capacity compared to other neuronal populations
Therapeutic Implications
Understanding α-syn's role in synaptic vesicle dysfunction has led to therapeutic strategies:
Small molecule inhibitors: Compounds that prevent α-syn aggregation
Immunotherapies: Antibodies targeting pathological α-syn species
Gene therapy: Approaches to modulate α-syn expressionAmyotrophic Lateral Sclerosis and Synaptic Dysfunction
ALS presents unique synaptic vesicle cycle abnormalities that contribute to motor neuron degeneration. Both familial and sporadic forms of ALS show[@kaur2022]:
Vesicle Pool Depletion: Reduced number of synaptic vesicles in motor neuron terminals
Impaired Vesicle Recycling: Endocytosis defects limit vesicle replenishment
Synaptic Protein Mislocalization: SNARE proteins show abnormal distribution
The VAMP2 (synaptobrevin) protein has been implicated in ALS pathogenesis, with mutations in VAMP2 associated with neurodevelopmental disorders affecting synaptic function.
Molecular Mechanisms of Vesicle Cycle Dysregulation
Calcium Signaling Abnormalities
Calcium (Ca²⁺) dysregulation is a common feature in neurodegenerative diseases that profoundly impacts synaptic vesicle function:
Elevated Resting Calcium: Chronic elevation of basal Ca²⁺ levels in neurons leads to:
- Impaired vesicle re-acidification
- Reduced release probability
- Dysregulated synaptotagmin function
Ca²⁺ Buffering Deficits: Changes in calbindin, parvalbumin, and other calcium-binding proteins alter the kinetics of calcium signaling, affecting the precise timing of neurotransmitter release.
Mitochondrial Dysfunction and Energy Depletion
The synaptic vesicle cycle is energetically demanding, requiring:
- ATP for V-ATPase function
- ATP for vesicle transport via molecular motors
- Energy for neurotransmitter synthesis and loading
Mitochondrial dysfunction in neurodegeneration reduces ATP availability, impairing these critical processes. The high energy demands of sustained vesicle cycling make synapses particularly vulnerable to metabolic stress.
Membrane Lipid Alterations
Changes in lipid composition of synaptic membranes affect:
- Vesicle fusion efficiency
- SNARE complex dynamics
- Synaptotagmin membrane interactions
In neurodegenerative diseases, altered lipid metabolism contributes to membrane properties that impair synaptic vesicle cycle function.
Therapeutic Targets and Drug Development
Modulation of Synaptic Vesicle Proteins
Several therapeutic strategies target components of the synaptic vesicle cycle[@brenner2022]:
| Target | Strategy | Status |
|--------|----------|--------|
| Synaptotagmin-1 | Ca²⁺ binding modulators | Preclinical |
| SNARE complex | Stabilizing peptides | Preclinical |
| V-ATPase | Proton pump enhancers | Research phase |
| VMAT2 | L-DOPA/carbidopa | Approved for PD |
| VGLUT | Transporter modulators | Research phase |
Gene Therapy Approaches
Viral vector-mediated gene delivery targeting synaptic proteins:
- AAV vectors encoding wildtype SNARE components
- siRNA approaches to reduce pathological protein expression
- CRISPR-based editing of disease-causing mutations
Small Molecule Modulators
Synaptotagmin Modulators: Compounds that enhance synaptotagmin's calcium sensitivity
SNARE Stabilizers: Small molecules that promote SNARE complex assembly
Vesicle Cycle Enhancers: Drugs that improve vesicle recycling kinetics
Measurement Techniques and Biomarkers
Electrophysiological Approaches
- Patch clamp recordings: Measure postsynaptic responses
- Miniature EPSC/IPSC analysis: Quantal properties
- Paired-pulse facilitation: Release probability assessment
Imaging Methods
- FM dye labeling: Vesicle dynamics visualization
- Electron microscopy: Synaptic ultrastructure
- Super-resolution microscopy: Protein localization
Biochemical Markers
- CSF neurotransmitters: Levels reflect synaptic function
- Vesicle proteins in blood: Potential peripheral biomarkers
- SNARE complexes: Assembled vs. disassembled states
Future Directions
Understanding Synaptic Vulnerability
Why certain neurons are more vulnerable to synaptic vesicle cycle dysfunction remains an important question:
Neuronal subtype-specific properties: Different neurons have varying capacities for vesicle cycling
Activity-dependent stress: High firing rates increase vulnerability
Protein expression patterns: Regional differences in synaptic protein expressionBiomarker Development
Synaptic vesicle proteins as biomarkers:
- Cerebrospinal fluid SNARE complexes
- Blood-derived synaptic vesicles
- Imaging of synaptic density using PET ligands
Therapeutic Optimization
Future therapies will likely combine:
- Multiple targets within the vesicle cycle
- Disease-modifying approaches with symptomatic relief
- Personalized medicine based on genetic and biomarker profiles
Detailed Molecular Mechanisms
Synaptotagmin Family in Disease Context
The synaptotagmin family consists of at least 17 isoforms in humans, with Synaptotagmin-1 (SYT1) being the primary calcium sensor for fast synchronous neurotransmitter release. In neurodegenerative contexts[@shin2022]:
Synaptotagmin-1 in Alzheimer's Disease: Aβ oligomers directly bind to the C2B domain of SYT1, competitively inhibiting calcium binding. This leads to:
- Reduced release probability
- Impaired synchronous release
- Elevated asynchronous release
Synaptotagmin-7 in Neurodegeneration: This isoform mediates asynchronous release and has been implicated in:
- Extended time windows for neurotransmitter release
- Potential compensatory mechanisms when SYT1 is impaired
- Differential vulnerability in different brain regions
Complexin and Synaphin in Synaptic Regulation
Complexin (CPLX) and synaphin play critical regulatory roles in synaptic vesicle cycling:
Complexin Function:
- Binds to assembled SNARE complexes
- Prevents full zippering until calcium-triggered activation
- Acts as a "clamp" that maintains vesicles in a primed state
Disease Implications:
- Altered complexin levels in AD and PD
- Mutations in complexin genes associated with neurological disorders
- Therapeutic potential of complexin modulators
Endophilins and Amphiphysin in Endocytosis
The endocytic phase of the synaptic vesicle cycle relies on specialized proteins[@saheki2012]:
Endophilins:
- Promote membrane curvature
- Sense and generate curvature through amphipathic helices
- Interact with dynamin and synaptojanin
Amphiphysin:
- BAR domain proteins that shape membranes
- Coordinate clathrin coat assembly
- Link to cytoskeletal elements
In Neurodegeneration:
- Altered expression in AD and PD
- Autoantibodies in certain neurological conditions
- Potential therapeutic targets for synaptic recovery
Quantitative Aspects of Synaptic Vesicle Cycling
Vesicle Pools and Kinetics
The presynaptic terminal maintains distinct vesicle pools with different kinetic properties:
Readily Releasable Pool (RRP):
- 5-20 vesicles per terminal in central nervous system
- Rapid depletion with sustained stimulation
- Refilled through replenishment mechanisms
Reserve Pool:
- Hundreds of vesicles per terminal
- Mobilized during high-frequency stimulation
- Dependent on actin cytoskeleton dynamics
Recycling Pool:
- Approximately 10-20% of total vesicles
- Directly recycled without passing through endosomes
- Essential for sustained synaptic transmission
Energetic Requirements
Each synaptic vesicle cycle consumes significant energy:
| Process | ATP Consumption |
|---------|-----------------|
| Vesicle acidification (V-ATPase) | ~10-15 ATP per vesicle |
| Neurotransmitter loading | 2-4 ATP per molecule |
| Vesicle transport | 1-2 ATP per step |
| SNARE assembly | Energy from zippering |
Temporal Dynamics
Fast Synaptic Transmission:
- Vesicle fusion: < 0.5 ms after Ca²⁺ entry
- Release site clearance: 1-2 ms
- Vesicle retrieval: 5-10 s
Plasticity Time Scales:
- Facilitation: 100-500 ms
- Depression: 100-500 ms
- Augmentation: 10-30 s
- Long-term potentiation: minutes to hours
Comparative Neurobiology of Synaptic Transmission
Evolution of Synaptic Machinery
The basic molecular machinery of synaptic vesicle cycling is evolutionarily conserved, with key proteins showing remarkable homology across species:
Conservation of SNARE Complex:
- VAMP2/synaptobrevin: >90% conserved from invertebrates to humans
- Syntaxin-1: High conservation across vertebrates
- SNAP-25: Two isoforms with distinct developmental expression
Divergence in Regulatory Proteins:
- Synaptotagmin isoforms expanded in vertebrates
- Complexin family shows species-specific adaptations
- Unique regulatory mechanisms in different neuronal types
Species Differences in Synaptic Physiology
Rodent vs. Human Synapses:
- Larger vesicle pools in human cortical synapses
- Differences in release probability
- Variations in short-term plasticity mechanisms
Relevance to Disease Modeling:
- Rodent models show partial conservation of human disease mechanisms
- Important caveats in translating findings across species
- Need for humanized models and iPSC-derived neurons
Clinical Implications
Biomarkers of Synaptic Dysfunction
Synaptic dysfunction represents an early event in neurodegeneration, making synaptic markers valuable for:
Diagnostic Biomarkers:
- CSF neurofilament light chain (NfL)
- CSF SNAP-25 and synaptotagmin fragments
- Blood synaptic proteins (exosomes)
Progression Markers:
- Longitudinal CSF sampling
- Imaging synaptic density with PET
- Electrophysiological markers
Therapeutic Monitoring
Measuring synaptic function provides insight into:
- Drug efficacy in clinical trials
- Disease progression rate
- Treatment response in individual patients
Synaptic Plasticity
The synaptic vesicle cycle is intimately linked to synaptic plasticity mechanisms:
- Long-term potentiation (LTP) requires functional vesicle cycling
- Long-term depression (LTD) involves vesicle pool modifications
- Homeostatic plasticity adjusts vesicle cycle parameters
Neuromodulation
Neuromodulators alter synaptic vesicle cycle properties:
- Dopamine modulates release probability
- Serotonin affects vesicle pool size
- Acetylcholine influences release kinetics
Conclusion
The synaptic vesicle cycle represents a fundamental process whose disruption underlies multiple neurodegenerative diseases. From Aβ-induced SNARE complex impairment in Alzheimer's disease to α-synuclein-mediated presynaptic dysfunction in Parkinson's disease, the molecular components of synaptic transmission offer numerous therapeutic targets. Understanding the detailed mechanisms of vesicle cycling, combined with advances in biomarker development and drug delivery, provides opportunities for developing disease-modifying treatments that preserve or restore synaptic function in neurodegenerative conditions.
References
[Südhof TC. The synaptic vesicle cycle. Annual Review of Neuroscience. 2013](https://doi.org/10.1146/annurev-neuro-060909-153258)
[Rothman JE. The membrane fusion puzzle. Trends in Cell Biology. 2014](https://doi.org/10.1016/j.tcb.2014.08.003)
[Jahn R, Fasshauer D. Molecular machines governing exocytosis. Nature. 2012](https://doi.org/10.1038/nature11018)
[Burré J, et al. Alpha-synuclein and SNARE complex assembly. Neuron. 2015](https://doi.org/10.1016/j.neuron.2015.09.004)
[Shin W, et al. Synaptotagmin-1 function. Neuron. 2022](https://doi.org/10.1016/j.neuron.2022.03.010)
[Saheki Y, De Camilli P. Synaptic vesicle endocytosis. Cold Spring Harbor Perspectives in Biology. 2012](https://doi.org/10.1101/cshperspect.a005645)
[Giraud P, et al. VGLUT transporters. Physiology. 2011](https://doi.org/10.1152/physiol.00038.2011)
[Miller MR, Sheng M. Synaptic vesicle proteins in disease. Acta Neuropathologica Communications. 2018](https://doi.org/10.1186/s40478-018-0551-z)
[Südhof TC. The molecular biology of synaptic transmission. Nature Reviews Neuroscience. 2021](https://doi.org/10.1038/s41583-021-00460-8)
[Rizo J. Mechanism of neurotransmitter release. Journal of Molecular Biology. 2022](https://doi.org/10.1016/j.jmb.2022.167512)
[Rizo J, Rosen MK. Molecular mechanisms of synaptic vesicle exocytosis. Annual Review of Cell and Developmental Biology. 2018](https://doi.org/10.1146/annurev-cellbio-100616-060516)
[Jack J, et al. Synaptic vesicle cycle dysfunction in Alzheimer's disease. Nature Reviews Neurology. 2023](https://doi.org/10.1038/s41582-023-00780-8)
[Calahorra F, et al. Alpha-synuclein and the SNARE complex. Journal of Molecular Neuroscience. 2021](https://doi.org/10.1007/s12031-021-01856-6)
[Kaur H, et al. Synaptic vesicle proteins in neurodegeneration. Frontiers in Molecular Neuroscience. 2022](https://doi.org/10.3389/fnmol.2022.895432)
[Zhang M, et al. Vesicle trafficking in Parkinson's disease. Cellular and Molecular Neurobiology. 2023](https://doi.org/10.1007/s10571-023-01312-2)
[Yang Y, et al. Synaptic vesicle endocytosis in neurodegenerative diseases. Progress in Neurobiology. 2024](https://doi.org/10.1016/j.pneurobio.2024.102538)
[Brenner S, et al. Synaptic vesicle dynamics in health and disease. Neuroscientist. 2022](https://doi.org/10.1177/10738584211063894)
[Choi ML, et al. Pathological alpha-synuclein and synaptic function. Brain. 2023](https://doi.org/10.1093/brain/awad015)
[West RJ, et al. Synaptic vesicle cycling in neurodegenerative disease. Journal of Neuroscience Research. 2019](https://doi.org/10.1002/jnr.24539)
[Chen X, et al. SNARE complexes in neurodegeneration. Current Opinion in Neurobiology. 2019](https://doi.org/10.1016/j.conb.2019.08.001)
- [Synaptic Transmission](/mechanisms/synaptic-transmission)
- [Synaptic Vesicle Trafficking](/mechanisms/synaptic-vesicle-trafficking)
- [Synaptic Dysfunction in Neurodegeneration](/mechanisms/cbs-synaptic-dysfunction)
- [Dopamine Metabolism in Parkinson's](/mechanisms/dopamine-metabolism-parkinson)
See Also
- [/proteins/synaptophysin](/proteins/synaptophysin)
- [/genes/snap25](/genes/snap25)
- [/proteins/snap25-protein](/proteins/snap25-protein)
- [/proteins/stxbp1](/proteins/stxbp1)
- [Synaptic Transmission](/mechanisms/synaptic-transmission)
- [Synaptic Vesicle Trafficking](/mechanisms/synaptic-vesicle-trafficking)
- [Synaptic Dysfunction in Neurodegeneration](/mechanisms/cbs-synaptic-dysfunction)
- [Dopamine Metabolism in Parkinson's](/mechanisms/dopamine-metabolism-parkinson)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)